BOOST Pharma ApS Financials, key figures and credit report
Gross profit -7 557.6 kDKK FY 2025 -244.6% vs 2024
EBIT -9 579.6 kDKK FY 2025 -148.3% vs 2024
Net debt 5 311.5 kDKK FY 2025 +209.9% vs 2024
Quick ratio 3.9 FY 2025 +1 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -1 319.98 | -3 499.68 | -1 529.77 | -2 193.39 | -7 557.57 |
| Employee benefit expenses | - 693.67 | -1 087.27 | - 824.88 | -1 665.36 | -2 022.06 |
| EBIT | -2 013.65 | -4 586.95 | -2 354.65 | -3 858.75 | -9 579.63 |
| Other financial income | 0.37 | 0.01 | |||
| Other financial expenses | - 624.58 | - 634.61 | - 764.89 | - 916.72 | -1 247.12 |
| Pre-tax profit | -2 638.22 | -5 221.19 | -3 119.53 | -4 775.48 | -10 826.75 |
| Income taxes | 414.03 | 1 023.20 | 366.39 | 515.89 | 1 583.26 |
| Net earnings | -2 224.19 | -4 198.00 | -2 753.14 | -4 259.58 | -9 243.49 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Prepayments and accrued income | 14.76 | 15.75 | 15.93 | 15.54 | |
| Current other receivables | 299.74 | 54.23 | 53.62 | 77.34 | 189.76 |
| Current deferred tax assets | 414.03 | 1 023.20 | 1 389.58 | 515.89 | 1 583.26 |
| Short term receivables total | 713.77 | 1 092.18 | 1 458.95 | 609.16 | 1 788.56 |
| Cash and bank deposits | 7 109.23 | 3 221.91 | 757.79 | 7 016.12 | 5 418.36 |
| Cash and cash equivalents | 7 109.23 | 3 221.91 | 757.79 | 7 016.12 | 5 418.36 |
| Balance sheet total (assets) | 7 823.00 | 4 314.09 | 2 216.75 | 7 625.28 | 7 206.92 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 40.00 | 40.00 | 40.00 | 50.00 | 55.00 |
| Retained earnings | -63.35 | -2 287.54 | -6 485.54 | -2 829.98 | -2 662.05 |
| Profit of the financial year | -2 224.19 | -4 198.00 | -2 753.14 | -4 259.58 | -9 243.49 |
| Shareholders equity total | -2 247.54 | -6 445.54 | -9 198.68 | -7 039.56 | -11 850.53 |
| Non-current owed to group member | 9 758.80 | ||||
| Non-current other liabilities | 6 157.83 | ||||
| Non-current deferred tax liabilities | 6 487.16 | 11 120.73 | 12 018.17 | 7 457.65 | |
| Non-current liabilities total | 6 157.83 | 6 487.16 | 11 120.73 | 12 018.17 | 17 216.45 |
| Current loans from credit institutions | 3 643.41 | 3 883.62 | 971.01 | ||
| Current trade creditors | 141.45 | 227.69 | 139.16 | 189.35 | 469.39 |
| Current owed to participating | 2 182.65 | ||||
| Other non-interest bearing current liabilities | 127.85 | 161.16 | 155.54 | 274.68 | 400.60 |
| Current liabilities total | 3 912.71 | 4 272.47 | 294.70 | 2 646.68 | 1 841.00 |
| Balance sheet total (liabilities) | 7 823.00 | 4 314.09 | 2 216.75 | 7 625.28 | 7 206.92 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated